New sickle cell disease drug approved for use in England – here’s how voxelotor works

By Johan Flygare, Associate Senior Lecturer, Division of Molecular Medicine and Gene Therapy, Lund University

A drug that can treat severe sickle cell disease has recently been given approval by the National Institute for Health and Care Excellence (Nice). Up to 4,000 patients in England living with sickle cell disease will now be offered voxelotor (also known under the brand name Oxbryta) to alleviate their symptoms.

Sickle cell disease is a genetic condition that affects red blood cells, causing them to deform into a sickle shape. This can block blood…

Read complete article

~	Cairo fears a ‘boomerang effect’ of pro-Palestine protests

~	MediSecure data breach: why is health data so lucrative for hackers?

~	What’s the difference between fiscal and monetary policy?

~	Has logging really stopped in Victoria? What the death of an endangered glider tells us

~	Three activists on why they refuse to be silent in older age

~	Our research shows what the rental market is really like for international students

~	Is it time for Australia to reassess its position on France’s role in New Caledonia?

~	Iraq: Repeal Anti-LGBT Law

~	Iran crash: President Raisi reported dead – what that might mean for the country and region

~	The ‘dead internet theory’ makes eerie claims about an AI-run web. The truth is more sinister